Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population
Trastuzumab deruxtecan led to greater survival outcomes than chemotherapy treatment of physician’s choice (TPC)* in patients with HER2-low** advanced breast cancer, according to results of a phase III trial presented at ASCO 2022.
Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population
14 Jul 2022
Thermoelectric warming therapy beneficial in MGD-related dry eye disease
A device that applies consistent emissive heat to the meibomian glandular apparatus appears to produce significant improvements in the signs and symptoms of dry eye disease in patients with meibomian gland dysfunction (MGD), with the benefits sustained over 6 months following treatment initiation, as shown in a study.
Thermoelectric warming therapy beneficial in MGD-related dry eye disease
14 Jul 2022
PSA testing helps prevent prostate cancer deaths
A prostate specific antigen (PSA)-based screening is effective in significantly lowering the risk of death from prostate cancer (PC), reports a study. However, nonattendance, initiation after age 60 years, and discontinuation at age 70 years appear to increase such risk.
PSA testing helps prevent prostate cancer deaths
14 Jul 2022
Disrupted gut fungi tied to colorectal cancer
Alterations in normal gut mycobiota profile, particularly the enrichment of the pathogenic Aspergillus rambellii, appear to aggravate the risk of colorectal cancer (CRC), according to a recent study.
Disrupted gut fungi tied to colorectal cancer
14 Jul 2022
Panitumumab + mFOLFOX6 ups OS in 1L left-sided RAS wild-type mCRC in Japanese trial
Panitumumab plus modified FOLFOX6 (mFOLFOX6; fluorouracil, leucovorin, and oxaliplatin) as first-line therapy significantly improves overall survival (OS) vs bevacizumab plus mFOLFOX6 in patients with left-sided RAS wild-type (wt) metastatic colorectal cancer (mCRC), results of the Japanese PARADIGM trial have shown.
Panitumumab + mFOLFOX6 ups OS in 1L left-sided RAS wild-type mCRC in Japanese trial
14 Jul 2022
Upadacitinib works in select ankylosing spondylitis patients
The Janus kinase inhibitor upadacitinib induces significantly higher response than placebo in ankylosing spondylitis patients with inadequate response to biological disease-modifying antirheumatic drugs, without introducing new safety signals, according to data from a phase III trial.